Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-563-7746
Dr. Kadia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2005 - 2008
Baylor College of MedicineResidency, Internal Medicine, 2001 - 2005
Rutgers Robert Wood Johnson Medical SchoolClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2004 - 2026
OK State Medical License 2020 - 2021
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Clinical Trials
- Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2010 Jun 08
- Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) Start of enrollment: 2010 Aug 01
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2012 Feb 07
Publications & Presentations
PubMed
- Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.Jacob E Herstein, Kayleigh R Marx, Fadi G Haddad, Kelly S Chien, Danielle Hammond
Leukemia & Lymphoma. 2026-02-02 - Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.Tapan M Kadia, Akhil Jain, Caitlin R Rausch, Alex Bataller, Farhad Ravandi
Blood Neoplasia. 2026-02-01 - Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia.Guillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla, Yue Wei, Kelly S Chien
Blood Cancer Discovery. 2026-01-26
Journal Articles
- Response Kinetics and Factors Predicting Survival in Core-Binding Factor LeukemiaHagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature
Abstracts/Posters
- Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk MyelofibrosisTapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Di...Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Less Is MoreASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Authored Content
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Press Mentions
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid MalignancesDecember 8th, 2025- Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025November 4th, 2025
- Naveen Pemmaraju: MECOM Fusion Partner and Bone Marrow Blast Percentage Influence Outcomes of Patients with MECOMSeptember 24th, 2025
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
